Home
|
News Room
|
Contact Us
Advanced Search
About AdvaMed
About Our Industry
News Room
Code of Ethics
Resources
Case Studies
Careers
Staff
|
Issues & Advocacy
Policy Positions
Comments & Testimony
FDA & Regulatory
Medicare & Reimbursement
International
State Issues
Advocacy
Legal
|
Meetings & Events
Education
Conference Materials
|
Membership
Active Membership
Associate Membership
Emerging Growth Companies
|
Publications
|
Members Only
Member News
Staff Directory
Advocacy
Committees
For the Board of Directors
For Special Representatives
Issues & Advocacy
Policy Positions
Comments & Testimony
FDA & Regulatory
Premarket
Postmarket
Science & Tech
FDA & Regulatory Alerts
Medicare & Reimbursement
International
State Issues
Advocacy
Legal
Adjust font size:
A
A
A
E-Mail to a Friend
Printer-friendly page
Members Only
Not registered?
Register now
!
Home
>
Issues & Advocacy
>
FDA & Regulatory
>
Science & Tech
> Combination Products
Combination Products
03/20/06
AdvaMed responses to FDA request for comments to the draft concept paper on “Postmarket Safety Reporting for Combination Products”
(pdf)
07/08/05
AdvaMed's submitted written comments and proposals concerning cross-labeling for combination technologies
Part 1
(pdf)
Part 2
(pdf)
08/20/04
AdvaMed Comments Concerning Combination Products and 'Primary Mode of Action' Rule
(pdf)
02/26/04
AdvaMed Comments to FDA on Office of Combination Products' Annual Report to Congress
(pdf)
07/08/03
Testimony at FDA Workshop 'Innovative Systems delivery of Drugs and Biologics: Scientific, Clinical, and Regulatory Challenges
(pdf)
